Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland

ConclusionUsing hypothetical willingness-to-pay thresholds of CHF 100,000 –150,000 per QALY gained, the present analysis has shown tisagenlecleucel to be a cost-effective treatment option in pALL and DLBCL.

Source: Advances in Therapy - May 22, 2021 Category: Drugs & Pharmacology Source Type: research